Bionano Genomics (BNGO) Projected to Post Quarterly Earnings on Wednesday

Bionano Genomics (NASDAQ:BNGO) is expected to announce its Q1 2026 results after the market closes on Wednesday, May 13th. Analysts expect the company to announce earnings of ($0.88) per share and revenue of $6.5680 million for the quarter. Investors can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 4:30 PM ET.

Bionano Genomics (NASDAQ:BNGO) last announced its earnings results on Monday, March 23rd. The company reported ($0.03) earnings per share for the quarter, beating the consensus estimate of ($0.81) by $0.78. Bionano Genomics had a negative net margin of 92.59% and a negative return on equity of 56.22%. The company had revenue of $7.95 million during the quarter, compared to the consensus estimate of $7.88 million.

Bionano Genomics Trading Down 1.6%

NASDAQ:BNGO opened at $1.27 on Tuesday. Bionano Genomics has a 12 month low of $1.06 and a 12 month high of $5.50. The firm has a fifty day simple moving average of $1.19 and a 200-day simple moving average of $1.41. The company has a current ratio of 1.98, a quick ratio of 1.74 and a debt-to-equity ratio of 0.08. The company has a market capitalization of $14.08 million, a P/E ratio of -0.27 and a beta of 1.62.

Wall Street Analyst Weigh In

Several research firms have recently commented on BNGO. HC Wainwright lowered their price objective on shares of Bionano Genomics from $7.00 to $6.00 and set a “buy” rating for the company in a research note on Monday, April 13th. Weiss Ratings upgraded shares of Bionano Genomics from a “sell (e)” rating to a “sell (e+)” rating in a research note on Friday, May 1st. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Bionano Genomics presently has a consensus rating of “Hold” and a consensus price target of $6.00.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Carret Asset Management LLC lifted its position in Bionano Genomics by 76.4% during the fourth quarter. Carret Asset Management LLC now owns 44,100 shares of the company’s stock valued at $67,000 after purchasing an additional 19,100 shares during the period. Jane Street Group LLC acquired a new position in Bionano Genomics during the fourth quarter valued at $34,000. Renaissance Technologies LLC acquired a new position in Bionano Genomics during the fourth quarter valued at $57,000. Geode Capital Management LLC lifted its position in Bionano Genomics by 148.8% during the fourth quarter. Geode Capital Management LLC now owns 66,766 shares of the company’s stock valued at $102,000 after purchasing an additional 39,928 shares during the period. Finally, DRW Securities LLC acquired a new position in Bionano Genomics during the fourth quarter valued at $258,000. 11.35% of the stock is currently owned by institutional investors and hedge funds.

About Bionano Genomics

Bionano Genomics, Inc (NASDAQ: BNGO) develops and commercializes high‐resolution genome analysis tools designed to map structural variants and large‐scale genomic rearrangements. At the core of its technology is the Saphyr® optical genome mapping system, which uses nanochannel arrays to linearize megabase‐length DNA molecules, proprietary fluorescent labeling reagents to highlight specific sequence motifs, and advanced image processing software to detect structural changes with high sensitivity.